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Background: Cell death induced by poly(ADP-ribose) (PAR) and mediated by apoptosis-inducing factor (AIF) is
well-characterized in models of ischemic tissue injury, but their roles in cancer cell death after chemotherapy are
less understood.
Methods: Here we investigated the roles of PAR and AIF by RNA interference (RNAi) in MDA-MB-231 and MCF-7
breast adenocarcinoma cells after chemotherapy. Differences in effects were statistically tested by analysis-of-
variance and unpaired student’s t-test.
Results: Silencing of AIF by RNAi led to decreased MDA-MB-231 and MCF-7 breast cancer cell death after
chemotherapy, which demonstrates a critical role for AIF. RNAi silencing of PAR glycohydrolase (PARG), the primary
enzyme that catalyzes the hydrolysis of PAR, led to increased PAR levels but decreased cell death. Further
investigation into the possible role of PAR in apoptosis revealed decreased caspase-3/7/8/9 activity in PARG-null
cells. Interestingly, the pharmacologic inhibition of caspase activity in PARG-silenced breast cancer cells led to
increased cell death after chemotherapy, which indicates that an alternative cell death pathway is activated due to
elevated PAR levels and caspase inhibition. AIF silencing in these cells led to profound protection from
chemotherapy, which demonstrates that the increased cell death after PARG silencing and caspase inhibition was
mediated by AIF.
Conclusions: The results show a role for AIF in breast cancer cell death after chemotherapy, the ability of PAR to
regulate caspase activity, and the ability of AIF to substitute as a primary mediator of breast cancer cell death in the
absence of caspases. Thus, the induction of cell death by PAR/AIF may represent a novel strategy to optimize the
eradication of breast tumors by activating an alternative cell death pathway.
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The ability to induce alternative pathways of cell death
in tumors after chemotherapy is potentially an innova-
tive strategy to optimize cancer cell death. Such
optimization could lead to the improved eradication of
tumors or the successful chemotherapeutic treatment of
cancer cells that evade apoptotic cell death. One contro-
versial, yet potentially novel, cell death pathway is poly
(ADP-ribose) (PAR)-dependent cell death mediated by* Correspondence: dwkoh@wsu.edu
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reproduction in any medium, provided the orapoptosis-inducing factor (AIF). The synthesis of PAR
by the PAR polymerases (PARPs) [1] is essential for the
maintenance of genomic integrity after cell stress. In the
absence of stress, AIF has a physiologic role in the mito-
chondria, as it contains NADH oxidase activity [2] and it
is involved in oxidative phosphorylation [3]. However,
therapeutic doses of DNA-damaging chemotherapeutic
agents activate the synthesis of PAR and ultimately leads
to the translocation of AIF from the mitochondria to the
nucleus [4]. Once AIF translocates to the nucleus, it has
a cytotoxic role, where it becomes part of a DNA frag-
menting complex that initiates caspase-independent celld. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a unique programmed cell death pathway known as
“necroptosis” [6].
Although some of the downstream cellular morpho-
logical changes in AIF-mediated cell death are similar to
those characteristic of apoptosis, such as chromatin con-
densation, DNA fragmentation, and phosphatidylserine
exposure [7], a unique feature of this cell death pathway
is that it can occur in the absence of caspases [8]. In fact,
AIF was the first protein reported to mediate a caspase-
independent form of programmed cell death [7]. This
observation remains controversial, as initial studies
demonstrated AIF-mediated cell death to be caspase-
independent [4,7], while later studies demonstrated it to
be dependent of caspases [9,10]. To date, cell death
studies support the possibility that AIF contributes to
caspase-dependent cell death and it induces an alterna-
tive form of apoptosis that is caspase-independent [11].
Another unique feature of AIF-mediated cell death is
its dependence on the synthesis of PAR. Studies have
shown that AIF fails to translocate to the nucleus in the
absence of PAR synthesis [12,13]. We recently showed
that the genetic disruption of PAR glycohydrolase
(PARG), the primary enzyme that catalyzes hydrolysis of
PAR [14], leads to increased levels of PAR and cell death
mediated by AIF [15]. Further, PAR was shown to bind
AIF, which leads to its release from the mitochondria
[16]. PAR is primarily synthesized in the nucleus by the
PARPs in response to DNA damage, and PAR causes the
mitochondrial release of AIF. These observations suggest
that nuclear PAR translocates to the mitochondria and
directly acts as the signal for AIF release. This PAR-
dependent cell death that is mediated by AIF is termed
“parthanatos” [17].
Current studies, however, suggest that PAR-induced
cell death mediated by AIF is only important in certain
cell types. For example, studies support a critical role for
AIF in the death of post-mitotic cells due to pathologic
conditions, such as tissue injury that occurs secondary
to ischemia [18], reperfusion injury [13], and various
conditions exacerbated by inflammation [19,20].The role
of AIF in cancer cell death after chemotherapy is less
understood. Studies indicate that chemotherapeutic
agents induce both caspase-dependent and caspase-
independent cell death in cancer cells [21,22], and that
AIF plays a critical role in the cell death of only a few
types of tumor cells [23-25]. Thus, it is unknown if AIF
can serve as a primary mediator of cell death in breast
cancer cells after chemotherapeutic treatments.
Here, we show a significant role for AIF-mediated cell
death induced by PAR in the death of invasive breast
cancer cells. Further, we demonstrate that AIF can sub-
stitute as caspase executioner in these cells in response
to chemotherapy and in the absence of caspase activity.In addition, we show that the inability to catalyze the hy-
drolysis of PAR negatively regulates caspase activity,
which provides further insight into the ability of PAR
and AIF to cause cell death in cancer cells in the absence
of caspases. Thus, cell death initiated by PAR and
mediated by AIF is potentially a novel strategy to induce
an alternative pathway of cell death in breast tumors.
Results
Silencing of AIF by RNAi leads to decreased nuclear
translocation of AIF after DNA damage
Because the genetic disruption of the AIF gene causes
embryonic lethality [4], no AIF-null breast cancer cells
are available. However, using the previously reported
protocol to silence the expression of AIF in melanocytes
by RNAi [26], we successfully decreased AIF levels in
human breast adenocarcinoma cells (Figure 1). Follow-
ing AIF RNAi oligo treatment, AIF protein levels were
significantly decreased after 48 h in MDA-MB-231
(Figure 1A-a) and MCF-7 cells (Figure 1B-a). Densito-
metric analysis of protein levels indicated greater
than 80% knockdown of AIF in MDA-MB-231 cells
(Figure 1A-b) and approximately 65% knockdown of AIF in
MCF-7 cells (Figure 1B-b) after RNAi treatment as com-
pared to untransfected (Con) or scrambled (Scr) RNAi
controls. Because AIF translocates from the mitochondria
to the nucleus following cytotoxic doses of the DNA-
methylating agent, N-methyl-N’-nitro-N-nitrosoguanidine
(MNNG) [12], we next analyzed levels of AIF in the nuclei
of MDA-MB-231 cells after MNNG treatment. No AIF
was observed in the nuclei of untreated cells, but a dose of
0.5 mM MNNG x45 min led to significant levels of AIF in
the nuclei of control and scrambled RNAi-treated cells
(Figure 1C). However, nuclear AIF in AIF-silenced
cells was significantly decreased. These results dem-
onstrate that RNAi silencing of AIF in breast adeno-
carcinoma cells leads to decreased AIF levels and
decreased levels of nuclear AIF after treatment with
a cytotoxic DNA-damaging agent.
Silencing of AIF by RNAi leads to decreased cell death
after treatment with DNA-damaging chemotherapeutic
agents
We next analyzed the effect of AIF silencing on cell
death in MDA-MB-231 and MCF-7 cells after treatment
with chemotherapeutic agents. MNNG and UV radiation
are two DNA-damaging treatments known to induce
PAR synthesis and AIF-mediated cell death [12,15,27].
The silencing of AIF by RNAi led to a 27% decrease in
cell death after MNNG treatment in MCF-7 cells
(Figure 2A). In MDA-MB-231 cells after AIF RNAi, a
30% decrease in cell death was observed after MNNG
treatment and a 25% reduction was observed after treat-
ment with UV radiation (Figure 2B). These results
Figure 1 Silencing of apoptosis-inducing factor (AIF) by siRNA in human breast adenocarcinoma cells. Human breast adenocarcinoma
cells were transfected with 20 nM small interfering RNA (siRNA) oligos for AIF as previously reported [26]. A, (a) Immunoblotting detection of AIF in
MDA-MB-231 cell extracts 48 h after siRNA transfection using polyclonal anti-AIF antibody (Rockland Immunochemcials) (1:1000 dilution). Controls
were provided by untransfected cells (Con) and cells transfected with scrambled siRNA oligos (Scr). Densitometric quantification (b) of AIF protein
bands from (a) was then performed. Values represent AIF/actin ratios of the densitometric intensities of the protein bands. *P< 0.01 between Scr
and AIF (one-way ANOVA and unpaired Student’s t test). Error bars represent the standard error of the mean (SEM). B, Immunoblotting detection
(a) and densitometric quantification of AIF in MCF-7 cell extracts 48 h after siRNA transfection. C, MDA-MB-231 cells were transfected with siRNA
oligos, treated with 0.5 mM N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) for 45 min, then analyzed by immunoblot for levels of nuclear AIF.
Controls for cell fractionations were provided by mitochondrial manganese superoxide dismutase (MnSOD) and nuclear lamin B2. PN, post-nuclear
fraction (cytoplasm+mitochondria); Nuc, nuclear fraction. All experiments were repeated at least three times with similar results.
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oma cells after DNA-damaging treatments. We then
treated MDA-MB-231 cells with the chemotherapeutic
agents epirubicin (EPI), cyclophosphamide (CPA), or cis-
platin (DDP), all of which are utilized in treating breast
cancer [28,29]. AIF silencing led to a 25% reduction in
cell death after DDP treatment (Figure 2C). However, a
more profound reduction in cell death was observed
after EPI or CPA treatment, where AIF knockdown led
to a 55-60% reduction in cell death. To confirm that
these effects were mediated by a decrease in the pro-cell
death function of AIF, nuclear AIF levels were analyzed
in these cells. The results demonstrate no significant
levels of AIF in the nuclei of MDA-MB-231 cells after
AIF silencing and EPI treatment (Figure 2D), whichindicates that the protective effects observed after AIF
silencing were due to decreased levels of AIF-mediated
cell death. Taken together, these results demonstrate an
important role for AIF in the death of breast adenocar-
cinoma cells after chemotherapy.
Silencing of PARG by RNAi leads to increased and
prolonged levels of PAR after treatment with
DNA-damaging agents
The ability of AIF to mediate cell death is dependent on
the synthesis of PAR. Also, our previous studies demon-
strated that treatment of PARG-null cells with DNA-
damaging agents led to increased levels of PAR and cell
death mediated by AIF [15]. Thus, we next investigated
the effects of the silencing of PARG, the primary enzyme
Figure 2 Chemotherapeutic treatment of human breast adenocarcinoma cells after the silencing of AIF. Cells were transfected with siRNA
for 48 h as before. A, MCF-7 cells were then treated with 0.5 mM MNNG x45 min. B, MDA-MB-231 cells were then treated with MNNG or 25 J/m2
UV-C radiation. After 24 h, cell death was quantified by FACS after propidium iodide (PI)/annexin V-FITC staining. C, MDA-MB-231 cells were
treated with 20 μM epirubicin (EPI) x6 h, 10 mM cyclophosphamide (CPA) x24 h, or 0.5 mM cisplatin (DDP) x6 h after siRNA transfection. Cell
death was then quantified by FACS after PI/annexin staining. For A-C, *P< 0.01 between Scr and AIF (one-way ANOVA and unpaired Student’s
t test). Error bars represent the SEM. D, Analysis of nuclear AIF levels in siRNA transfected cells treated with EPI. Con, untransfected cells; Scr,
scrambled siRNA transfected cells. All experiments were repeated at least twice with similar results.
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MDA-MB-231 breast cancer cells. The results demon-
strated that the silencing of PARG by RNAi decreased
PARG levels approximately 70% in MDA-MB-231 cells
(Figure 3A and B). Analysis of PAR levels after MNNG
treatment in control cells demonstrated peak levels of
PAR at 0.5 h, with a decrease in PAR levels from 1–8 h
thereafter (Figure 3C, a). In PARG silenced cells, how-
ever, a high level of PAR was observed in untreated cells
(Figure 3C, b). After MNNG treatment, PAR levels
decreased from 0.5 – 4 h, which indicates PARG activity.
However, at all time points except 24 h, PAR levels were
significantly elevated in PARG silenced MDA-MB-231
cells as compared to control cells (Figure 3D). These
results thus demonstrate that RNAi silencing of PARG
leads to increased levels of PAR in MDA-MB-231 breast
cancer cells after treatment with cytotoxic doses of the
DNA-damaging agent, MNNG.
Silencing of PARG by RNAi leads to decreased levels of
cell death and increased levels of procaspase-8 after DNA
damage
We next determined the effect of PARG silencing on cell
death in MDA-MB-231 cells. Surprisingly, PARG silen-
cing led to a 43% decrease in cell death after MNNG
treatment (Figure 4A). In the same experiment, control
cells pretreated with Q-VD-OPh, a pan-caspase inhibitor[30], also led to a 43% decrease in cell death in MDA-
MB-231 cells after MNNG treatment (Figure 4A). Be-
cause of the similarities, we next analyzed the effect of
PARG knockdown or the genetic disruption of PARG on
caspase activity and and procaspase levels in these cells.
Procaspase-8 is an initiator caspase that must be acti-
vated by proteolytic cleavage [31]. Following PARG si-
lencing by RNAi in MDA-MB-231 cells, increased levels
of procaspase-8 were observed as compared to untrans-
fected control cells after MNNG treatment (Figure 4B).
Quantification of procaspase-8 protein levels by densito-
metric analysis confirmed this observation (Figure 4C).
This level of procaspase-8 in PARG-silenced cells was
similar to the level observed after pretreatment with Q-
VD-OPh, which suggests that the silencing of PARG led
to decreased activation of procaspase-8 after MNNG
treatment. This possible effect of PARG silencing on
procaspase-8 levels prompted us to investigate the effect
of the genetic deletion of PARG on caspase activity. We
previously demonstrated increased levels of PAR and
decreased levels of caspase-3/7 activity in PARG-null
cells after UV treatment [15]. We next investigated
caspase-8 and −9 activity in PARG-null cells after treat-
ment with UV radiation. Previously, UV-C radiation was
shown to activate both intrinsic and extrinsic pathways
of apoptosis [32]. Thus, this treatment is sufficient to
characterize caspase-8 and −9 activity, the initiator
Figure 3 Silencing of poly(ADP-ribose) glycohydrolase (PARG) by siRNA in MDA-MB-231 cells. MDA-MB-231 cells were transfected with
siRNA oligos for PARG as previously reported [38]. A, Immunoblotting detection of PARG in cell extracts 48 h after transfection using polyclonal
anti-PARG antibody (Millipore) (1:2,000 dilution). Equivalent controls wereutilized as in Fig. 1A. B, Densitometric quantification of PARG protein
bands from A. *P< 0.01 between Scr and AIF (one-way ANOVA and unpaired Student’s t test). Error bars represent the SEM. C, MDA-MB-231 cells
were transfected with PARG siRNA oligos, treated with 0.5 mM MNNG, then analyzed for levels of PAR by immunoblot from 0.5-24 h. Equal
protein loading per lane was verified by immunoblotting detection of β-actin. D, Densitometric quantification of PAR levels from C. *P< 0.01
between Scr and PARG (one-way ANOVA and unpaired Student’s t-test). Error bars represent the SEM.
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ways, respectively. As the positive control for decreased
caspase activity, we again observed decreased caspase-3
/7 activity in PARG-null cells after UV-C radiation
(Fig. 4D-a). However, we also observed decreased levels
of caspase-8 and caspase-9 activity in PARG-null cells
after UV-C treatment (Figure 4D-b and c). These
decreased levels of caspase-8/9 activity were similar to
the levels observed after PARG-null cells were pretreated
with Q-VD-OPh, which indicates that increased levels of
PAR due to the absence of PARG leads to the negative
regulation of caspase-8/9 activity. These results thus
demonstrate that the absence of PARG leads to decreased
caspase-3, -7, -8, and −9 activity after DNA-damaging
treatments. Taken together, these results suggest that theknockdown or genetic deletion of PARG, which both lead
to increased levels of PAR, leads to decreased caspase ac-
tivity after DNA damage. Further, they suggest that the de-
crease in cell death observed in PARG-silenced cells after
MNNG treatment was due to the inhibition of caspase-
mediated apoptotic cell death by elevated levels of PAR.
Thus, the hydrolysis of PAR by PARG appears to have a
role in regulating caspase activity after DNA-damaging
treatments in breast adenocarcinoma cells.
The silencing of PARG in combination with the inhibition
of caspases leads to increased cell death in MDA-MB-231
cells after MNNG treatment that is mediated by AIF
Since increased levels of PAR due to the RNAi silen-
cing or genetic knockout of PARG led to decreased
Figure 4 Analysis of cell death and caspases in MDA-MB-231 cells after PARG silencing or genetic disruption. A, MDA-MB-231 cells
pretreated with the pan-caspase inhibitor, Q-VD-OPH (Q), were transfected with PARG siRNA. 48 h after transfection, cells were treated with
0.5 mM MNNG for 45 min, and 24 h later cell death was quantified by FACS. All error bars represent the SEM. *P< 0.01 between Scr and PARG or
Scr and Scr +Q (one-way ANOVA and unpaired Student’s t-test). B, extracts from cells in A were probed for the immunoblotting detection of
procaspase-8 levels. C, Procaspase-8 protein levels in B were quantified by densitometric analysis. Values represent procaspase-8/actin ratios of
the densitometric intensities of the protein bands. D, Wild-type (WT) and PARG-null (KO) cells were treated with 25 J/m2 UV-C radiation and 12 h
later caspase-3 (a), caspase-8 (b), and caspase-9 (c) activity was assayed. Q, pretreatment with Q-VD-OPh 30 min prior to UV treatment and until
caspase activity assays. Error bars represent the SEM. *P< 0.01 between WT and KO (one-way ANOVA and unpaired Student’s t-test). RFU, relative
fluorescence unit.
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of pan-caspase inhibition on cell death in PARG-
silenced MDA-MB-231 cells after DNA-damaging
treatments. Interestingly, the results showed that the
pretreatment of PARG-silenced cells with Q-VD-OPh
lead to an increase in MDA-MB-231 cell death after
MNNG treatment (Figure 5A). This level of cell death
was comparable to the amount of cell death observed
in control cells treated with MNNG, as PARG-silenced
cells pretreated with Q-VD-OPh (49%), untransfected
cells (48%), and cells transfected with scrambled RNAi
oligos (55%) all produced similar levels of cell death
after MNNG treatment (Figure 5A). These results sug-
gest that an alternative cell death pathway is induced
after the silencing of PARG and the inhibition of cas-
pases, such that it can substitute as the cell death exe-
cutioner after MNNG treatment in the absence of
caspase activity.
To identify this alternative cell death pathway in the
absence of caspase activity, we performed the silencing
of AIF by RNAi in PARG-silenced MDA-MB-231 cells
pretreated with Q-VD-OPh. The results demonstratethat the silencing of AIF in these cells led to a profound
amount of protection from MNNG treatment, since
the amount of cell death observed was only 16%
(Figure 5A). This was significantly decreased as com-
pared to the level of cell death in PARG-silenced cells pre-
treated with Q-VD-OPh (50%). This indicates that AIF is
a primary mediator of cell death that occurs after the in-
hibition of caspase activity in PARG-silenced cells. Fur-
ther, the decrease in cell death due to AIF silencing (66%)
was greater than the decrease in cell death observed in
PARG-silenced cells (43%) or control cells (cells trans-
fected with scrambled RNAi oligos) pretreated with
Q-VD-OPh (49%). This indicates that AIF is respon-
sible for mediating the majority of cell death that is
observed after chemotherapy in PARG-silenced MDA-
MB-231 cells in the absence of caspases.
A closer inspection of cell death in MDA-MB-231 cells
after knockdown or inhibition of caspases, PARG, and
AIF was performed by analyzing the amount of cells that
exhibited propidium iodide (PI) and/or annexin V-FITC
fluorescence after FACS analysis. The results revealed
that the inhibition of caspases in control cells (via
Figure 5 MDA-MB-231 cell death after silencing of PARG,
inhibition of caspases, and RNAi knockdown of AIF. MDA-MB-
231 cells were pretreated with Q-VD-OPh and transfected with
siRNA for PARG and AIF. A, Cell death was quantified by FACS after
treatment with 0.5 mM MNNG for 45 min. B, The percentage of cells
that exhibited propidium iodide (PI), annexin V-FITC, or dual PI/
annexin V-FITC fluorescence from FACS analysis in B were
determined. C, Extracts from cells in A were probed for the
immunoblotting detection of PARG, AIF, and procaspase-3. SDS-
PAGE loading controls were provided by the immunoblotting
detection of β-actin. All error bars represent the SEM. *P< 0.01
between Scr vs. Scr +Q, PARG vs. PARG+Q, PARG+Q vs.
PARG+Q+AIF, PARG+Q+AIF vs. PARG, and PARG+Q+AIF vs.
Scr +Q (one-way ANOVA and unpaired Student’s t-test).
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PARG by siRNA led to a decreased amount of cells that
exhibited dual PI/annexin V fluorescence (Figure 5B).
This indicates decreased levels of caspase-mediated
apoptotic cell death. However, the combination of
PARG-silencing and Q-VD-OPh treatment led to
increased PI/annexin V staining, which would normally
indicate increased levels of apoptosis. However, caspase
inhibition via Q-VD-OPh pretreatment was confirmed
by immunoblot, as procaspase-3 levels were decreased
after MNNG treatment (due to caspase-3 activation),
but were not decreased after the pretreatment of PARG-
silenced cells with Q-VD-OPh (Figure 5C). This demon-
strates that caspase-mediated apoptosis was not the pri-
mary type of cell death induced in PARG-silenced cells
pretreated with Q-VD-OPh. The addition of AIF-
silencing in these cells led to decreased levels of PI/
annexin V staining (Figure 5B). The silencing of PARG
and AIF protein levels by RNAi were confirmed by
immunoblot (Figure 5C). Since AIF-mediated necropto-
sis also leads to the dual staining of cells with PI/annexin
V [5], these results thus demonstrate that AIF is the pri-
mary mediator of cell death in PARG-silenced cells pre-
treated with Q-VD-OPh. Taken together, these results
demonstrate that AIF can substitute as the primary me-
diator of cell death in PARG-silenced MDA-MB-231
cells in the absence of caspases, and it potentially identi-
fies a critical role for AIF in the death of breast adeno-
carcinoma cells after chemotherapy.
Discussion
Our results identify a potentially novel role for AIF in
the death of breast cancer cells after chemotherapy.
Here, we demonstrated a role for AIF in the death of
breast adenocarcinoma cells after treatment with cis-
platin, cyclophosphamide, or epirubicin, all currently uti-
lized chemotherapeutic agents used to treat breast
cancer [28,29]. The potential importance of AIF in
breast cancer cell death is also seen in its ability to medi-
ate cell death in the absence of caspase activity. Previ-
ously, it was shown that AIF can substitute as caspase
executioner in ischemicneuronal injury mediated by N-
methyl-D-aspartate (NMDA) receptor stimulation after
the inhibition of caspase activity [18]. Likewise, the
results here demonstrate the ability of AIF to substitute
as caspase executioner in breast cancer cell death after
increasing PAR levels and pretreatment with the pan-
caspase inhibitor, Q-VD-OPh. The ability of AIF to me-
diate caspase dependent or caspase independent cell
death is controversial. Initial studies demonstrated that
the ability of AIF to induce cell death was caspase-
independent [7,18], while subsequent studies demon-
strated it was caspase-dependent [9,10]. This study pro-
vides further evidence for the ability of AIF to induce
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paper presents evidence that AIF is an important medi-
ator of breast cancer cell death after chemotherapy in
the absence of caspases, and it also identifies a role for
AIF in the mediation of caspase-independent cell death
in breast adenocarcinoma cells.
These results reveal the potential ability for the
pharmacologic activation of AIF to improve the che-
motherapeutic treatment of breast cancer. Because of
the dependence of nuclear AIF translocation on the syn-
thesis of PAR, a feasible strategy to induce AIF-mediated
cell death would appear to be elevating PAR levels by
inhibiting PARG, the primary enzyme that catalyzes the
hydrolysis of PAR, to improve the chemotherapeutic re-
sponse. The modulation of PAR levels was shown to
primarily affect rapidly dividing cells [33], which demon-
strates the ability of the targeting of PAR to selectively
target cancer cells. Our previous studies suggest that en-
hancing the synthesis of PAR may provide an improved
strategy to successfully treat breast tumors due to the
ability of PAR to activate AIF-mediated cell death. How-
ever, our data here shows that the silencing of PARG by
RNAi leads to increased breast cancer cell survival. This
is in agreement with a previous study that demonstrated
that the silencing of PARG by RNAi in murine embry-
onic fibroblasts decreased cell death following hydrogen
peroxide (H2O2) treatment [34]. However, most studies
regarding the genetic disruption or knockdown of PARG
demonstrate increased cell death. Stable knockdown of
PARG by short hairpin RNA (shRNA) caused increased
cell death following apoptotic doses of H2O2[35] and
radiosensitivity to X-rays [36]. Genetic disruption of the
Parg gene causes embryonic lethality and increased cell
death in response to low doses of DNA-damaging agents
[37,38]. Recently, we demonstrated the specific induc-
tion of AIF-mediated cell death in PARG-null cells after
UV-C radiation [15]. Thus, the knockdown or genetic
disruption of PARG is known to have a deleterious effect
on cancer cells.
However, we provide evidence that PARG activity has
a role in increasing caspase activity, such that the knock-
down or absence of PARG leads to decreased levels of
caspase activity and decreased levels of apoptotic cell
death. This suggests that PARG may have multiple roles
in the regulation of caspase-dependent and caspase-
independent cell death. The difference in cell death ver-
sus cell survival after the silencing or absence of PARG
may reflect differential roles for PARG isoforms on the
modulation of cell death. The Parg gene is unique, but
alternative splicing leads to five different PARG isoforms
that localize to different cellular compartments [39]. Al-
though the function of each is poorly understood, stud-
ies have identified a role for the nuclear isoform in DNA
repair and the maintenance of genomic integrity [40],and a role for the cytoplasmic PARG isoforms to regu-
late the translation and stability of mRNAs after cell
stress[41]. It is therefore possible that each PARG iso-
form may have a role in different pathways of cell death.
Thus, while the nuclear PARG isoform may have a role
in genomic stability and the regulation of caspase-
independent cell death, the cytoplasmic isoforms may
have roles in regulating caspase function in the cytosol
in response to cell stress. Therefore, the specific inhib-
ition of the nuclear PARG isoform may be required to
optimize cell death in breast cancer cells in response to
chemotherapeutic treatments.
This study utilized MNNG, which is an experimental
chemotherapeutic agent only. However, it is a DNA-
methylating agent that also induces free radical-
mediated oxidative stress[42], which is similar to the
mechanism of other DNA-alkylating chemotherapeutic
agents[43]. It is also a well-established inducer of PAR
metabolism and AIF-mediated cell death[12,33]. Al-
though MNNG is not clinically utilized, it is an appro-
priate agent to utilize in order to study the molecular
pathways of cell death in breast cancer cells mediated by
PAR. Further, the similar mechanism of action that
MNNG shares with other currently utilized DNA-
alkylating chemotherapeutic agents indicates that
MNNG is suitable for initial studies regarding the che-
motherapeutic relevance of PAR/AIF in breast cancer
cells. However, future preclinical studies expanding on
our findings will be required to utilize currently used
clinical agents.
Finally, the results provide novel insight into the ability
of PAR to potentially regulate apoptosis. PAR was ini-
tially associated with caspases due to the specific cleav-
age of PARP-1 into 24 and 89 kDa forms by caspase 3
during apoptosis [44]. However, cells lacking PARP-1
were shown to undergo caspase-dependent apoptosis
normally following stimuli that activate intrinsic or ex-
trinsic apoptotic pathways [45]. Thus, a direct role for
PAR in caspase-dependent cell death was not known.
Here, we demonstrate the ability of PAR to negatively
regulate caspase activity. Because PAR was shown to in-
duce the translocation of AIF to the nucleus following
genotoxic stress [12], it is possible that the absence of
PARG, which leads to elevated levels of PAR, leads to
the modulation of caspase activity and activates the nu-
clear translocation of AIF. Such a scenario, which
requires further investigation, would provide novel
insight into the mechanism of how cell death induced by
PAR and mediated by AIF is caspase-independent.
Conclusions
This study demonstrates a role for the pro-cell death
mediator, AIF, in breast cancer cell death after chemo-
therapy. Further, the results demonstrate the novel
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pase activity. We therefore report novel roles for AIF
and PAR in the death of breast adenocarcinoma cells
after chemotherapy. Moreover, we report the ability of
AIF to substitute as primary mediator of breast cancer
cell death in the absence of caspases after chemotherapy.
Thus, these results identify the relevance of AIF in
breast cancer cell death and they suggest that cell death
by PAR/AIF may represent a strategy to optimize the




Dulbecco’s modified Eagle’s medium (DMEM) was pur-
chased from Hyclone (Logan, UT). OptiMEM reduced
serum medium was purchased from Gibco (Grand Is-
land, NT). Fetal bovine serum (FBS) was purchased from
Atlas Biologicals (Fort Collins, CO). Protease inhibitor
cocktail tablets (Complete Mini, EDTA-free) were from
Roche (Mannheim, Germany). Caspase inhibitor, Q-VD-
OPh, was purchased from R&D Systems (Minneapolis,
MN). Lipofectamine2000 reagent, trypsin, penicillin-
streptomycin solution, and glutamine were purchased
from Invitrogen (Carlsbad, CA). N-Methyl-N’-nitro-N-
nitrosoguanidine (MNNG) was purchased from AccuS-
tandard (New Haven, CT). Epirubicin, cisplatin and
cyclophosphamide were all purchased from Calbiochem
(La Jolla, CA). ApoScreen annexin V-fluorescein isothio-
cyanate (FITC) conjugate and propidium iodide (PI)
were purchased from Southern Biotech (Birmingham,
AL). Primary antibodies utilized were polyclonal anti-
PAR clone 96–10 (Trevigen, Gaithersburg, MD), poly-
clonal anti-β-actin (Thermo Fisher Scientific), polyclonal
anti-caspase-3 (Millipore, Billerica, MA), monoclonal
anti-PARG (Millipore), polyclonal anti-AIF (Rockland
Immunochemicals, Gilbertsville, PA), polyclonal anti-
manganese superoxide dismutase (MnSOD) (Millipore),
monoclonal anti-Lamin B2 clone LN43 (Thermo Fisher),
and monoclonal anti-caspase-8 (Cell Signaling, Danvers,
MA). Secondary antibodies horseradish peroxidase
(HRP)-conjugated goat anti-rabbit and anti-mouse were
purchased from Sigma (St. Louis, MO).
Cell Culture
Human breast adenocarcinoma cells (MDA-MB-231 and
MCF-7) were cultured in DMEM supplemented with
10% FBS, 2 mM L-glutamine and 100U/ml penicillin/
streptomycin at 37°C in 5% CO2. Wild type and PARG-
null primary embryonic trophoblast stem (TS) cells were
derived from E3.5 mouse blastocysts and cultured as
previously described [33]. For siRNA transfections, each
cell line was cultured at least one day in antibiotic-free
medium before transfection.RNA interference
The silencing of AIF by RNAi was performed as previ-
ously reported using sense (5’-CUUGUUCCAGCGAU
GGCAUtt-3’) and antisense (5’-AUGCCAUCGCUGGAA
CAAGtt-3’) RNA oligos that target nucleotides 151–
171 in human AIF [26]. The silencing of PARG by
RNAi was performed as previously reported using RNA
oligos 5’-AAATGGGACTTTACAGCTTTG-3’) that tar-
get nucleotides 1960–1980 in human PARG [34]. Control
oligos 5’-AGACAGAAGACAGAUAGGCtt-3’ (sense) and
5’-GCCUAUCUGUCUUCUGUCUtt-3’ (antisense) were
used for all negative controls [26]. All RNA oligos
were purchased as duplexed RNA from Sigma-Aldrich
(St. Louis, MO). Each siRNA duplex was resuspended
in RNAase-free H2O at a final concentration of 20 μM
and stored at −20°C.
For RNAi transfections, cells were plated in 0.5 ml
medium per well without antibiotics in 24-well plates
one day before transfection. At the time of transfection,
cells were approximately 50% confluent. For each trans-
fection, duplex siRNA was added to 50 μl OptiMEM
medium and 1 μl lipofectamine2000 was added to 50 μl
OptiMEM. After 5 min, the two solutions were gently
mixed and then incubated at room temperature for
20 min. Final concentrations of siRNA were 20 nM for
AIF and 40 nM for PARG. The mixtures were added to
each well and cells were cultured for an additional 48–
72 h.
Whole cell lysate extraction
Cells were harvested by trypsinization, washed with PBS,
suspended in lysis buffer containing 10 mM Tris–HCl
(pH8), 0.1 M NaCl, 1 mM EGTA, 1 mM EDTA, 0.1% tri-
ton X-100, and protease inhibitors (Complete Protease
Inhibitor Cocktail tablets, Roche). Extracts were then
incubated on ice for 30 min with vortexing every 10 min.
Cleared cell lysates were obtained after centrifugation at
16,000 xg for 10 min. SDS-PAGE sample buffer was added
to supernatants to achieve final concentrations of 50 mM
Tris–HCl with pH 6.8, 1% SDS, 2.5% glycerol, 0.002% bro-
mophenol blue, and 143 mM 2-mercaptoethanol. Samples
were then boiled for 2 min at 100°C.
Subcellular Fractionations
Cells were harvested by trypsinization and washed with
PBS. Pellets were fractionated using the NE-PER Nuclear
and Cytoplasmic Extraction Kit (Pierce, Rockfield, IL)
according to the manufacturer’s protocol. Nuclear and
cytoplasmic fractions were prepared in SDS sample buf-
fer and boiled as previously described.
Immunoblotting
Approximately 20 μg of each lysate or subcellular sam-
ple was subjected to 8-12% sodium dodecyl sulfate
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proteins were transferred to nitrocellulose by semi-dry
transfer at 25 V for 1 h using a Trans-blot SD apparatus
(BioRad, Hercules, CA). Membranes were blocked with
PBS containing 5% milk and 0.1% Tween-20 (PBST) at
room temperature for 1 h and incubated with primary
antibodies (1:2000 anti-AIF, 1:2000 anti-PARG, 1:3000
anti-MnSOD, 1:1000 anti-LaminB2, 1:10,000 anti-PAR,
1:10000 anti-beta-actin, 1:2000 anti-caspase3 or 1:2000
anti-caspase-8) in PBST+ 5% milk overnight (shaking) at
4°C. Membranes were then washed with PBST three
times and incubated with horseradish peroxidase (HRP)-
conjugated goat anti-rabbit or anti-mouse antibody
(1:10000) for 1 h. The membranes were washed as
described above, and chemiluminescence was initiated
using the Supersignal West Pico reagents (Pierce).
Immunoblots were then developed on a ChemiDoc XRS
gel imaging system (Bio-Rad). For quantification of pro-
tein levels for each blot, immunoblots were examined by
densitometry with the ChemiDoc imager using Quantity
One software. Relative densitometry ratios were then
calculated using β-actin as loading controls. The result-
ing AIF/actin, PARG/actin, or procaspase-8/actin values
were then used to quantify relative protein levels.
Cell Viability Assay
Forty-eight hours after cells were transfected with
siRNA, cells were treated with 0.5 mM MNNG, an ex-
perimental chemotherapeutic agent that methylates
DNA [42] and is known to induce PAR-mediated cell
death [12,33,46]. Cells were also treated with 20 μM
epirubicin (EPI), a dose similar to those used in MDA-
MB-231 breast cancer cells in previous reports [47,48]
and consistent with the reported IC50 of this agent in
breast cancer cells (55.3 μM) [49]. Other treatments
consisted of 10 mM cyclophosphamide (CPA), a dose
previously utilized in MDA-MB-231 breast cancer cells
[50], or 0.5 mM cisplatin (DDP), an elevated dose for
this agent, but the exposure time utilized (6 hr) was 4 to
12-fold less than normally indicated (24–72 hr). Further,
this dose of DDP was consistent with the reported IC50
of this agent in breast cancer cells (0.6 mM) [51].
Twenty hours after treatment, cells were harvested,
washed with PBS, and resuspended in annexin-binding
buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM
CaCl2,) to approximately 1 X 10
6 cells/ml. For each
100 μl of cell suspension, 2.5 μl of ApoScreen annexin
V-FITC conjugate solution (Southern Biotech) and 1 μl
of 100 μg/ml propidium iodide (PI) solution was added.
Cells were then incubated at room temperature for
15 min and 400 μl annexin-binding buffer was added.
Cell death was then measured by quantifying the per-
centage of cells that exhibited annexin V-FITC and/or PI
fluorescence using a flow cytometer (Accuri, Ann Arbor,MI). Total cell death was quantified by adding the per-
centage of cells detected in the upper left (PI), upper
right (PI + annexin V-FITC), and lower right (annexin V-
FITC) quadrants in the FACS dot plots. For pretreat-
ment with Q-VD-OPh, cells were treated with 40 μM Q-
VD-OPh 30 min prior to chemotherapeutic treatments.
Treatment with Q-VD-OPh continued during all treat-
ments, and until FACS analyses were performed.
Caspase Activity Assay
Wild type and PARG null TS cells were cultured and
exposed to 25 J/m2 UV-C using a low-pressure Hg lamp
(model G30T8, Sylvania, Danvers, MA). 12 h after UV
exposure, 1 X 105 cells were seeded in 96-well opaque
black plate and subjected to Apo-ONE Homogeneous
Caspase-3/7, Caspase-8, and Caspase-9 Assays (Pro-
mega) according the manufacturer’s specifications.
Fluorescence was analyzed using a Bio-Tek (Winooski,
VT) Synergy HT plate reader at an excitation wave-
length of 485 nm and at an emission wavelength of
527 nm. Negative controls were provided by untreated
cells and cells pretreated with 40 μM Q-VD-OPh.
Statistical analyses
All error bars for calculated cell death, caspase activity,
and protein levels represented the standard error of the
mean (SEM). Statistical analyses were accomplished by
one-way analysis of variance (ANOVA) and unpaired
Student’s t-test.
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